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C7Nmoieties are wildly present as pharmacophores in natural products. In this issue of Chemistry & Biology,
Rui and colleagues biochemically reproduced the initiation event of asukamycin biosynthesis and character-
ized tandem enzymatic oxygenations of the epoxyquinone C7N moiety.Many families of microbial secondary
metabolites owe their diverse bioactivities
to the presence of pharmacologically
active C7N moieties. These C7N moieties
are present in various structural forms
and synthesized through different enzy-
matic routes (Figure 1). The large family
of ansamycins, such as the anti-tubercu-
losis rifamycin and antitumor ansamito-
cin, use 3-amino-5-hydroxybenzoic acid
(3,5-AHBA) as the starter unit to initiate
the polyketide chain assembly en route
to the C7N pharmarcophore. 3,5-AHBA
is synthesized from UDP-glucose and
glutamine by a dedicated set of enzymes
through a route similar to the shikimate
pathway (Figure 1A) (Floss, et al., 2011).
So far, the reported modifications that
occur at the 3,5-AHBA moieties of
ansamycins include quino reduction and
glycolate unit addition (rifamycin), haloge-
nation and O-methylation (ansamitocin),
and hydroxylation (rubradirin) (Kang,
et al., 2012).
C7N moieties are also found in the
family of aminocylitol natural products
exemplified by the antidiabetic acarbose
and antifungal validamycin. The C7N
units are derived from the pentose
phosphate pathway with sedo-heptulose
7-phosphate as the immediate precursor
to generate 2-epi-5-epi-valiolone, which
subsequently undergoes further modi-
fications to produce the C7N moieties
with significant structural variations
(Figure 1B). These enzymatic modifica-
tions include epimerization, dehydration,
glycosylation, hydroxylation, and epoxy-
dation (Flatt and Mahmud, 2007).
The manumycin-type metabolites,
including manumycin and asukamycin,
are a new family of C7N-containing natural
products that display antibacterial, anti-coccidal, antifungal, and other attractive
activities. This type of compound shows
unique features with an epoxyquinone
meta-C7N moiety, a ‘‘lower’’ polyketide
chain, an ‘‘upper’’ polyketide chain, and
a C5N ring linked to the ‘‘lower’’ chain
(Sattler, et al., 1998). Previous intensive
synthetic and feeding experiments
done by Floss and coworkers had
established 3-amino-4-hydroxybenzoic
acid (3,4-AHBA) as the putative starter
unit for the ‘‘lower’’ chain assembly and
protoasukamycin as a true late inter-
mediate (Figure 1C) (Hu and Floss,
2004). Recently, Rui et al. (2010) reported
the cloning of the 63.9 kb asukamycin
biosynthetic gene cluster and performed
a systematic inactivation of more than
17 genes, leading to a more rational
asukamycin biosynthetic pathway.
Similar to the biosynthetic studies of
other natural products, the in vivo gene
inactivation usually could not tell the
exact functions of each gene and espe-
cially the order or timing of each reaction
in the biosynthetic pathway. In this issue
of Chemistry & Biology, using elegant
enzymatic catalysis coupled with careful
LC-HRMS analysis, Rui et al. (2013)
clearly deciphered the process of 3,4-
AHBA activation and initiation of the
‘‘lower’’ chain assembly and the tandem
oxygenations involved in the epoxyqui-
none C7N formation.
In the asukamycin biosynthetic gene
cluster, asuA2 is the only gene coding
for adenylase and is considered to be
critical for the activation of 3,4-AHBA.
Using the classical ATP-[32P]PPi ex-
change assay, 3,4-AHBA and other four
aryl acids were found to be efficiently
adenylated by the heterologously ex-
pressed AsuA2, reflecting its catalyticChemistry & Biology 20, July 25, 2013promiscuity. Moreover, the two candidate
ACPs, AsuC11 and AsuC12, within the
cluster were expressed in holo forms
and tested to identify the cognate ACP
for AsuA2. Detected by LC-HRMS,
AsuC12 was shown to be the true
receptor for 3,4-AHBA and other four
aryl acids, whereas no reaction occurred
with AsuC11. However, asuC11 was
previously shown to be essential for
asukamycin biosynthesis through gene
inactivation, suggesting that AsuC11
may have other functions rather than
being an acyl-carrier protein.
The putative hydroxylase AsuE1 con-
verted protoasukamycin to 4-hydroxy-
protoasukamycin, a known intermediate
of asukamycin biosynthesis, in the
presence of NADPH and abundant
flavin. Under this circumstance, AsuE1
shows features of single-component
flavin-dependent monooxygenase by
equivalently reducing FAD, FMN, or ribo-
flavin. However, the presence of AsuE2,
a cognate flavin reductase, can replace
the exogenous flavin and requires only
the presence of bound FMN for the
hydroxylation by AsuE1, highlighting the
two-component nature of AsuE1. From
4-hydroxyprotoasukamycin to the final
asukamycin with the epoxyquinone C7N
moiety, an epoxidation at the C5-C6
position of 3,4-AHBA is required. In vitro
biochemical catalysis not only confirmed
that AsuE3 is the required epoxidase
with FMN as preferred flavin, but also
showed its stringent substrate specificity
for 4-hydroxyprotoasukamycin. More-
over, AsuE2 does not change the catalytic
efficiency of AsuE3, showing that AsuE3
is a single-component epoxidase.
The authors took a mutasynthesis
approach and fed the four aryl acidsª2013 Elsevier Ltd All rights reserved 859
Figure 1. Three Families of Natural Products with Different C7N Moieties
(A) Ansamycin-type natural products with 3,5-AHBA C7N moiety.
(B) Aminocyclitol-type natural products with 2-epi-5-epi-valiolone as intermediate.
(C) Manumycin-type natural products with epoxyquinone C7N moiety. The epoxyquinone moiety is high-
lighted with the square.
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nonproducing mutant. However, asuka-
mycin analogs with intact structures
were only identified in feeding experiment
with 3-aminobezonic acid (3-ABA), sug-
gesting the presence of highly specific
and ordered catalytic activities in ‘‘upper’’
chain attachment and incorporation of the
C5N unit. Further structure characteriza-860 Chemistry & Biology 20, July 25, 2013 ª2tion of 3-ABA derivatives actually proved
that hydroxylation or epoxidation does
not occur at the novel 3-ABA C7N moiety,
showing again the stringent substrate
specificity of AsuE1/E3. Interestingly, all
3-ABA derivatives lost inhibitory activity
against methicillin-resistant S. aureus,
validating epoxyquinone as a pharmaco-
logically active C7N moiety.013 Elsevier Ltd All rights reservedTogether with previous chemical and
genetic achievements, the biochemical
analysis carried out by Rui et al. (2013)
disclosed details on the biosynthesis of
manumycin-type antibiotics, which paves
the way for further structure/activity
modification and sheds new lights on
improving the fermentation titers of these
important drug leads.ACKNOWLEDGMENTS
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